Design, synthesis, and biological evaluation of novel conformationally constrained inhibitors targeting EGFR

ACS Medicinal Chemistry Letters

Volumn 4, Issue 10, 2013, Pages 974-978

  Wu, Jianwei ^a   Chen, Wenteng ^a   Xia, Guangxin ^b   Zhang, Jing ^b   Shao, Jiaan ^a   Tan, Biqin ^a   Zhang, Chunchun ^b   Yu, Wanwan ^a   Weng, Qinjie ^a   Liu, Haiyan ^b   Hu, Miao ^a   Deng, Hailin ^b   Hao, Yu ^b   Shen, Jingkang ^b,c   Yu, Yongping ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b Central Research Institute   (China)

^c SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

Anticancer; conformationally constrained; EGFR; kinase inhibitor

Indexed keywords

ACRYLAMIDE; ADENOSINE TRIPHOSPHATE; ENZYME INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; PROTEIN TYROSINE KINASE; QUINAZOLINE DERIVATIVE; SCAFFOLD PROTEIN;

ARTICLE; AUTOPHOSPHORYLATION; CANCER INHIBITION; CELL DIFFERENTIATION; CELL SURVIVAL; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG SYNTHESIS; ENZYMATIC ASSAY; ENZYME ACTIVITY; HINGE REGION; HUMAN; HYDROGEN BOND; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; NUCLEOPHILICITY; PRIORITY JOURNAL; PROTEIN TARGETING; TUMOR CELL LINE; TUMOR GROWTH; TUMOR VOLUME;

EID: 84885442412     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml4002437     Document Type: Article

References (21)

1. Olayioye, M. A.; Neve, R. M.; Lane, H. A.; Hynes, N. E. The ErbB signaling network: receptor heterodimerization in development and cancer EMBO J. 2000, 19, 3159-3167
2. Gschwind, A.; Fischer, O. M.; Ullrich, A. The discovery of receptor tyrosine kinases: targets for cancer therapy Nat. Rev. Cancer 2004, 4, 361-370
3. Adjei, A. A. Epidermal growth factor receptor tyrosine kinase inhibitors in cancer therapy Drugs Future 2001, 26, 1087-1092
4. Renhowe, P. A. Inhibitors of growth factor receptor kinase-dependent signaling pathways in anticancer chemotherapy-clinical progress Curr. Opin. Drug Discovery Dev. 2002, 5, 214-224
5. Ranson, M.; Hammond, L. A.; Ferry, D.; Kris, M.; Tullo, A.; Murray, P. I.; Miller, V.; Averbuch, S.; Ochs, J.; Morris, C.; Feyereislova, A.; Swaisland, H.; Rowinsky, E. K. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial J. Clin. Oncol. 2002, 20, 2240-2250
6. Ciardiello, F.; Tortora, G. A novel approach in the treatment of cancer: Targeting the epidermal growth factor receptor Clin. Cancer Res. 2001, 7, 2958-2970
7. Johnston, S. R. D.; Leary, A. Lapatinib: A novel EGFR/HER2 tyrosine kinase inhibitor for cancer Drugs Today 2006, 42, 441-453
8. Leproult, E.; Barluenga, S.; Moras, D.; Wurtz, J.-M.; Winssinger, N. Cysteine mapping in conformationally distinct kinase nucleotide binding sites: Application to the design of selective covalent inhibitors J. Med. Chem. 2011, 54, 1347-1355
9. Potashman, M. H.; Duggan, M. E. Covalent modifiers: An orthogonal approach to drug design J. Med. Chem. 2009, 52, 1231-1246
10. Smaill, J. B.; Showalter, H. D. H.; Zhou, H.; Bridges, A. J.; McNamara, D. J.; Fry, D. W.; Nelson, J. M.; Sherwood, V.; Vincent, P. W.; Roberts, B. J.; Elliott, W. L.; Denny, W. A. Tyrosine kinase inhibitors. 18. 6-Substituted 4-anilinoquinazolines and 4-anilinopyrido-[3,4- d ]pyrimidine as soluble, irreversible inhibitors of the epidermal growth factor receptor J. Med. Chem. 2001, 44, 429-440
11. Smaill, J. B.; Rewcastle, G. W.; Loo, J. A.; Greis, K. D.; Chan, O. H.; Reyner, E. L.; Lipka, E.; Showalter, H. D. H.; Vincent, P. W.; Elliott, W. L.; Denny, W. A. Tyrosine kinase inhibitors: 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazolineand 4-(phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions J. Med. Chem. 2000, 43, 1380-1397
12. Tsou, H. R.; Overbeek-Klumpers, E. G.; Hallett, W. A.; Reich, M. F.; Floyd, M. B.; Johnson, B. D.; Michalak, R. S.; Shen, R.; Shi, X.; Wang, Y. F.; Upeslacis, J.; Wissner, A. Optimization of 6,7-disubstituted-4-(arylamino) quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity J. Med. Chem. 2005, 48, 1107-1131
13. Wissner, A.; Overbeek, E.; Reich, M. F.; Floyd, M. B.; Johnson, B. D.; Mamuya, N.; Rosfjord, E. C.; Discafani, C.; Davis, R.; Shi, X.; Rabindran, S. K.; Gruber, B. C.; Ye, F.; Hallett, W. A.; Nilakantan, R.; Shen, R.; Wang, Y.; Greenberger, L. M.; Tsou, H. Synthesis and structure-activity relationships of 6,7-disubstituted 4-anilinoquinoline-3-carbonitriles: The design of an orally active, irreversible inhibitor of the tyrosine kinase activity of the epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor-2 (HER-2) J. Med. Chem. 2003, 46, 49-63
14. Engelman, J. A.; Zejnullahu, F.; Gale, C.-M.; Lifshits, E.; Gonzales, A. J.; Shimamura, T.; Zhao, F.; Vincent, P. W.; Naumov, G. N.; Bradner, J. E.; Althaus, I. W.; Gandhi, L.; Shapiro, G. I.; Nelson, J. M.; Heymach, J. V.; Meyerson, M.; Wong, K.-K.; Jänne, P. A. PF00299804, an irreversible Pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib Cancer Res. 2007, 67, 11924-31192
15. Li, D.; Ambrogio, L.; Shimamura, T.; Kubo, S.; Takahashi, M.; Chirieac, L. R.; Padera, R. F.; Shapiro, G. I.; Baum, A.; Himmelsbach, F.; Rettig, W. J.; Meyerson, M.; Solca, F.; Greulich, H.; Wong, K. K. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models Oncogene 2008, 27, 4702-4711
16. Li, D.; Lv, P.; Zhang, H.; Zhang, H.; Hou, Y.; Liu, K.; Ye, Y.; Zhu, H. The combination of 4-anilinoquinazoline and cinnamic acid: a novel mode of binding to the epidermal growth factor receptor tyrosine kinase Bioorg. Med. Chem. 2011, 19, 5012-5022
17. Ballard, P.; Barlaam, B.; Bradbury, R. H.; Dishington, A.; Hennequin, L. F.; Kickinson, D. M.; Hollinsworth, I. M.; Kettle, J. G.; Klinowska, T.; Ogilvie, D. J.; Pearson, S. E.; Scott, J. S.; Suleman, A.; Whittaker, R.; Williams, E. J.; Wood, R.; Wright, L. Neutral 5-substituted 4- anilinoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase Bioorg. Med. Chem. Lett. 2007, 17, 6326-6329
18. Barlaam, B.; Ballard, P.; Bradbury, R. H.; Ducray, R.; Germain, H.; Kickinson, D. M.; Hudson, K.; Kettle, J. G.; linowska, T. K.; Magnien, F.; Ogilvie, D. J.; Olivier, A.; Pearson, S. E.; Scott, J. S.; Suleman, A.; Trigwell, C. B.; Vautier, M.; Whittaker, R. D.; Wood, R. A new series of neutral 5-substituted 4-anilinoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase Bioorg. Med. Chem. Lett. 2008, 18, 674-678
19. Carey, K. D.; Garton, A. J.; Romero, M. S.; Kahler, J.; Thomson, S.; Ross, S.; Park, F.; Haley, J. D.; Gibson, N.; Sliwkowski, M. X. Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib Cancer Res. 2006, 66, 8163-8171
20. Tsou, H.-R.; Mamuya, N.; Johnson, B. D.; Reich, M. F.; Gruber, B. C.; Ye, F.; Nilakantan, R.; Shen, R.; Discafani, C.; DeBlanc, R.; Davis, R.; Koehn, F. E.; Greenberger, L. M.; Wang, Y.-F.; Wissner, A. 6-Substituted-4-(3- bromophenylamino)quinazolines epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor (HER-2) tyrosine kinases with enhanced antitumor activity J. Med. Chem. 2001, 44, 2719-2734
21. o J. Pharmacol. Toxicol. Methods 2004, 50, 187-199